sotorasib – Talk Bio

Actionable Insights Powered by AI

Revolutions KRAS drugs appear competitive in several lung cancer settings

4 months ago talkbio0Tagged Biological Markers, G12C inhibitors, K-ras Oncogene, KRAZATI, Lumakras, Non-Small Cell Lung Carcinoma, Rotation, sotorasib

KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines

FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer

10 months ago talkbio0Tagged amgen, G12C mutation, K-ras Oncogene, Lumakras, Metastasis from malignant neoplasm of colon and/or rectum, panitumumab, sotorasib, United States Food and Drug Administration, Vectibix

FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab